Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Filings indexed 493 across all filing types
Latest filing 2026-04-17 Annual Report
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics - Annual Report 2025 - Attachment: Nykode Therapeutics ASA - Annual Report 2025.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT' and contains comprehensive sections including a letter to shareholders, board of directors report, financial statements (income statement, balance sheet, cash flows), notes to financial statements, and an independent auditor's report. It covers the fiscal year 2025 and provides detailed financial and operational performance data, fitting the definition of a 10-K (Annual Report). FY 2025
2026-04-17 English
Nykode Therapeutics - Annual Report 2025
Report Publication Announcement Classification · 90% confidence The document is a short press release (3,008 characters) announcing the publication of the Annual Report for 2025 and providing links to download it, rather than containing the full report content itself. Under the “menu vs. meal” rule, this is a report publication announcement.
2026-04-17 English
Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity for Abi-Suva at ICHNO 2026 - Attachment: 260320 - ICHNO Press Release_FINAL.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Nykode Therapeutics announcing positive clinical trial results (Phase 1 dose escalation of abi-suva) presented at a medical conference (ICHNO 2026). It provides highlights of efficacy, safety, and immunogenicity data. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains the actual data highlights. It is best classified as a general regulatory announcement (RNS) for corporate news.
2026-03-20 English
Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity for Abi-Suva at ICHNO 2026
Regulatory Filings Classification · 95% confidence The document is a press release from Nykode Therapeutics announcing clinical trial results (Phase 1 dose escalation of abi-suva) presented at a medical conference (ICHNO 2026). It provides key highlights of efficacy and safety data. While it mentions that the presentation will be available on their website, the document itself is a corporate announcement of these results, which falls under the category of general regulatory announcements or corporate news updates. Given the specific categories provided, 'RNS' (Regulatory Filings) serves as the appropriate fallback for this type of corporate news release. FY 2026
2026-03-20 English
Nykode Therapeutics Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026 - Attachment: 260318 AACR and NextGen_FINAL.pdf
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding upcoming scientific presentations at medical conferences (AACR and NextGen Biomed). It provides details on the titles, dates, and locations of these presentations. It does not contain the actual presentation slides, but rather announces that they will be available on the company's website after the events. Since it is a general regulatory announcement that does not fit into specific financial reporting categories like 10-K or IR, and it is not a report itself but an announcement of upcoming events, it falls under the RNS (Regulatory Filings) category.
2026-03-18 English
Nykode Therapeutics Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026
Regulatory Filings Classification · 95% confidence The document is a press release announcing upcoming scientific presentations at medical conferences (AACR and NextGen Biomed). It does not contain financial results, board changes, or regulatory filings, but rather serves as a general corporate announcement regarding research and development activities. As it does not fit into specific categories like earnings releases or investor presentations, it falls under the general regulatory announcement category.
2026-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.